Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.
Journal: Hematology (Amsterdam, Netherlands)
Published: September 05, 2026
A model to estimate spleen volume from palpated spleen length in patients with myelofibrosis.
Journal: Annals of hematology
Published: April 01, 2026
Treatment patterns and blood count control in 10,112 patients with polycythemia vera.
Journal: Expert review of hematology
Published: June 13, 2025
Genetic and Epigenetic Dysregulation of CR1 is Associated with Catastrophic Antiphospholipid Syndrome (CAPS).
Journal: medRxiv : the preprint server for health sciences
Published: May 19, 2025
Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome.
Journal: Annals of the rheumatic diseases
Published: April 14, 2025
Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis.
Journal: Leukemia & lymphoma
Published: January 09, 2025
Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera.
Journal: The oncologist
Published: November 27, 2024
Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.
Journal: Acta haematologica
Published: October 28, 2024
Direct and indirect costs for patients with myeloproliferative neoplasms.
Journal: Leukemia & lymphoma
Published: April 27, 2024
Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis.
Journal: Acta haematologica
Published: February 06, 2024
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.
Journal: Journal of cellular and molecular medicine
Published: June 12, 2023
Last Updated: 09/26/2026